Characteristics of the included patients (n=23)
| Neurosarcoidosis diagnosis, n (%) | |
| Probable | 21 (91.3) |
| Definite | 2 (8.7) |
| Age at TNF-α inhibitor initiation, years, mean (SD) | 41.5 (10.4) |
| Sex ratio (M/F) | 10/13 |
| Time between diagnosis and TNF-α inhibitor initiation, months, median (IQR) | 22 (14–49.5) |
| Time of TNF-α inhibitor exposure, months, median (IQR) | 24 (17–40) |
| Location of parenchymal CNS lesion(s), no of patients (%) | |
| Isolated cerebral involvement | 8 (34.8) |
| Isolated spinal cord involvement | 5 (21.7) |
| Isolated pituitary/hypothalamic involvement | 3 (13) |
| Mixed | 7 (30.4) |
| Type of TNF-α inhibitor used, no of patients (%) | |
| Infliximab | 22 (95.7) |
| Adalinumab | 1 (4.3) |
| Treatments used just before TNF-α inhibitor, no of patients (%) | |
| Corticosteroids | 23 (100) |
| Methotrexate | 8 (34.8) |
| Cyclophosphamide | 4 (17.4) |
| Azathioprine | 2 (8.7) |
CNS, central nervous system; TNF-α, tumour necrosis factor-α.